KERYDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Kerydin, and when can generic versions of Kerydin launch?
Kerydin is a drug marketed by Anacor Pharms Inc and is included in one NDA.
The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tavaborole profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Kerydin
A generic version of KERYDIN was approved as tavaborole by ENCUBE on October 13th, 2020.
Summary for KERYDIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 96 |
| Clinical Trials: | 1 |
| Patent Applications: | 218 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for KERYDIN |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for KERYDIN |
| What excipients (inactive ingredients) are in KERYDIN? | KERYDIN excipients list |
| DailyMed Link: | KERYDIN at DailyMed |
Recent Clinical Trials for KERYDIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for KERYDIN
Paragraph IV (Patent) Challenges for KERYDIN
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| KERYDIN | Topical Solution | tavaborole | 5% | 204427 | 13 | 2018-07-09 |
US Patents and Regulatory Information for KERYDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anacor Pharms Inc | KERYDIN | tavaborole | SOLUTION;TOPICAL | 204427-001 | Jul 7, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for KERYDIN
When does loss-of-exclusivity occur for KERYDIN?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 06214247
Estimated Expiration: ⤷ Sign Up
Patent: 06333527
Estimated Expiration: ⤷ Sign Up
Patent: 10203096
Estimated Expiration: ⤷ Sign Up
Patent: 11200994
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0608431
Estimated Expiration: ⤷ Sign Up
Patent: 0621279
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 97982
Estimated Expiration: ⤷ Sign Up
Patent: 35680
Estimated Expiration: ⤷ Sign Up
China
Patent: 1160124
Estimated Expiration: ⤷ Sign Up
Patent: 1505603
Estimated Expiration: ⤷ Sign Up
Patent: 1914109
Estimated Expiration: ⤷ Sign Up
Patent: 2532180
Estimated Expiration: ⤷ Sign Up
Patent: 5949230
Estimated Expiration: ⤷ Sign Up
Patent: 6008571
Estimated Expiration: ⤷ Sign Up
Patent: 6008583
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 16454
Estimated Expiration: ⤷ Sign Up
Patent: 20695
Estimated Expiration: ⤷ Sign Up
Patent: 24503
Estimated Expiration: ⤷ Sign Up
Patent: 20027
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 53251
Estimated Expiration: ⤷ Sign Up
Patent: 76536
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
France
Patent: C1024
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 09735
Estimated Expiration: ⤷ Sign Up
Patent: 60139
Estimated Expiration: ⤷ Sign Up
Patent: 21956
Estimated Expiration: ⤷ Sign Up
Patent: 28917
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 26021
Estimated Expiration: ⤷ Sign Up
Patent: 40060
Estimated Expiration: ⤷ Sign Up
Patent: 54365
Estimated Expiration: ⤷ Sign Up
Patent: 000019
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 5080
Estimated Expiration: ⤷ Sign Up
Patent: 2402
Estimated Expiration: ⤷ Sign Up
Patent: 7156
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 38912
Estimated Expiration: ⤷ Sign Up
Patent: 46876
Estimated Expiration: ⤷ Sign Up
Patent: 09140
Estimated Expiration: ⤷ Sign Up
Patent: 08535781
Estimated Expiration: ⤷ Sign Up
Patent: 09526751
Estimated Expiration: ⤷ Sign Up
Patent: 10248265
Estimated Expiration: ⤷ Sign Up
Patent: 13018778
Estimated Expiration: ⤷ Sign Up
Patent: 14132031
Estimated Expiration: ⤷ Sign Up
Patent: 15117243
Estimated Expiration: ⤷ Sign Up
Patent: 16020374
Estimated Expiration: ⤷ Sign Up
Patent: 16199561
Estimated Expiration: ⤷ Sign Up
Patent: 17105826
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 343304
Estimated Expiration: ⤷ Sign Up
Patent: 2020524
Estimated Expiration: ⤷ Sign Up
Luxembourg
Patent: 0157
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 5993
Estimated Expiration: ⤷ Sign Up
Patent: 9262
Estimated Expiration: ⤷ Sign Up
Netherlands
Patent: 1049
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0448
Estimated Expiration: ⤷ Sign Up
Patent: 8297
Estimated Expiration: ⤷ Sign Up
Patent: 8441
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 53251
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 53251
Estimated Expiration: ⤷ Sign Up
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 14906
Estimated Expiration: ⤷ Sign Up
Patent: 06947
Estimated Expiration: ⤷ Sign Up
Patent: 07134429
Estimated Expiration: ⤷ Sign Up
Patent: 08131324
Estimated Expiration: ⤷ Sign Up
Patent: 10133524
Estimated Expiration: ⤷ Sign Up
Patent: 16145916
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 43304
Estimated Expiration: ⤷ Sign Up
Patent: 87796
Estimated Expiration: ⤷ Sign Up
Patent: 24932
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 0707408
Estimated Expiration: ⤷ Sign Up
Patent: 0905950
Estimated Expiration: ⤷ Sign Up
Patent: 1005380
Estimated Expiration: ⤷ Sign Up
Patent: 1506944
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1337045
Estimated Expiration: ⤷ Sign Up
Patent: 1337068
Estimated Expiration: ⤷ Sign Up
Patent: 1426220
Estimated Expiration: ⤷ Sign Up
Patent: 1456815
Estimated Expiration: ⤷ Sign Up
Patent: 070112390
Estimated Expiration: ⤷ Sign Up
Patent: 080110984
Estimated Expiration: ⤷ Sign Up
Patent: 100105869
Estimated Expiration: ⤷ Sign Up
Patent: 130095330
Estimated Expiration: ⤷ Sign Up
Patent: 130100019
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 14095
Estimated Expiration: ⤷ Sign Up
Patent: 40966
Estimated Expiration: ⤷ Sign Up
Patent: 86981
Estimated Expiration: ⤷ Sign Up
Patent: 72962
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering KERYDIN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 101505603 | Boron-containing small molecules | ⤷ Sign Up |
| Spain | 2414095 | ⤷ Sign Up | |
| Israel | 185080 | BORON-CONTAINING SMALL MOLECULES, PHARMACEUTICAL FORMULATIONS COMPRISING THEM AND USE THEREOF IN THE PREPARATION OF MEDICAMENTS FOR TREATING INFECTIONS | ⤷ Sign Up |
| Russian Federation | 2010133524 | БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ | ⤷ Sign Up |
| Japan | 2008535781 | ⤷ Sign Up | |
| Russian Federation | 2008131324 | БОРСОДЕРЖАЩИЕ МАЛЫЕ МОЛЕКУЛЫ | ⤷ Sign Up |
| Australia | 2006333527 | Boron-containing small molecules | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for KERYDIN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2343304 | 2090017-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REG. NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | PA2020524 | Lithuania | ⤷ Sign Up | PRODUCT NAME: KRISABOROLAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS FORMOJE; REGISTRATION NO/DATE: EU/1/19/1421 20200327 |
| 2343304 | C 2020 030 | Romania | ⤷ Sign Up | PRODUCT NAME: CRISABOROL SI SARURILE SALE FARMACEUTIC ACCEPTABILE FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: EU/1/19/1421; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1421; DATE OF FIRST AUTHORISATION IN EEA: 20200327 |
| 2343304 | 132020000000082 | Italy | ⤷ Sign Up | PRODUCT NAME: CRISABOROLO, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE(STAQUIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1421, 20200401 |
| 2343304 | CA 2020 00022 | Denmark | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | 20C1024 | France | ⤷ Sign Up | PRODUCT NAME: CRISABOROLE, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/19/1421 20200401 |
| 2343304 | C20200027 00352 | Estonia | ⤷ Sign Up | PRODUCT NAME: KRISABOROOL;REG NO/DATE: EU/1/19/1421 01.04.2020 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
